Published in:
Open Access
01-12-2022 | Care | Research
Effectiveness and cost-effectiveness of a telemedicine programme for preventing unplanned hospitalisations of older adults living in nursing homes: the GERONTACCESS cluster randomized clinical trial
Authors:
Caroline Gayot, Cécile Laubarie-Mouret, Kevin Zarca, Maroua Mimouni, Noelle Cardinaud, Sandrine Luce, Isabelle Tovena, Isabelle Durand-Zaleski, Marie-Laure Laroche, Pierre-Marie Preux, Achille Tchalla
Published in:
BMC Geriatrics
|
Issue 1/2022
Login to get access
Abstract
Objective
The GERONTACCESS trial evaluated the utility and cost-effectiveness of a gerontological telemedicine (TLM) programme for preventing unplanned hospitalisation of residents living in nursing homes (NHs) in regions lacking medical facilities and/or qualified medical providers (“medical deserts”).
Design
GERONTACCESS was a 12-month, multicentre, prospective cluster-randomised trial conducted in NHs. The intervention group underwent TLM assessments every 3 months. The control group received the usual care. In both groups, comprehensive on-site assessments were conducted at baseline and the final visit. Care requirements were documented throughout the study.
Setting and participants
NH residents aged ≥ 60 years with multiple chronic diseases.
Methods
The study outcomes were the proportion of patients who experienced avoidable and unplanned hospitalisation, and the incremental cost savings per quality-adjusted life years from baseline to the 12-month follow-up.
Results
Of the 426 randomised participants (mean ± standard deviation age, 87.2 ± 7.6 years; 311 [73.0%] women), 23.4% in the intervention group and 32.5% in the control group experienced unplanned hospitalisation (odds ratio [OR] = 0.73, 95% confidence interval [CI] 0.43 to 0.97; p = 0.034). Each avoided hospitalisation in the intervention group saved $US 3,846.
Conclusions and implications
The results of GERONTACCESS revealed that our gerontological, preventative TLM program significantly reduced unplanned hospitalisations. This innovative intervention limited disease progression and promoted a healthy lifestyle among NH residents.
Trial registration
Clinicaltrials.gov, NCT02816177, registered June 28, 2016.